北京大学学报(医学版) ›› 2022, Vol. 54 ›› Issue (6): 1214-1218. doi: 10.19723/j.issn.1671-167X.2022.06.026

• 病例报告 • 上一篇    下一篇

皮肌炎合并巨噬细胞活化综合征5例

邢晓燕1,张筠肖2,朱冯赟智1,王一帆1,周新尧3,李玉慧1,*()   

  1. 1. 北京大学人民医院风湿免疫科,北京 100044
    2. 北京市监狱管理局清河分局医院内科,天津 300481
    3. 中国中医科学院广安门医院风湿病科,北京 100053
  • 收稿日期:2022-08-31 出版日期:2022-12-18 发布日期:2022-12-19
  • 通讯作者: 李玉慧 E-mail:liyuhui84@163.com
  • 基金资助:
    北京大学人民医院研究与发展基金(RDX2020-03)

Clinical analysis of 5 cases of dermatomyositis complicated with macrophage activation syndrome

Xiao-yan XING1,Jun-xiao ZHANG2,Feng-yun-zhi ZHU1,Yi-fan WANG1,Xin-yao ZHOU3,Yu-hui LI1,*()   

  1. 1. Department of Rheumatology and Immunology, Peking University People' s Hospital, Beijing 100044, China
    2. Department of Internal Medicine, Beijing Prison Administration Qinghe Branch, Tianjin 300481, China
    3. Department of Rheumatology and Immunology, Guang' anmen Hospital of China Academy of Chinese Medical Sciences, Beijing 100053, China
  • Received:2022-08-31 Online:2022-12-18 Published:2022-12-19
  • Contact: Yu-hui LI E-mail:liyuhui84@163.com
  • Supported by:
    the Research and Development Fund of Peking University People's Hospital(RDX2020-03)

RICH HTML

  

关键词: 皮肌炎, 巨噬细胞活化综合征, 肌炎特异性抗体, 感染, 预后

Abstract:

To investigate the clinical and immunological features of dermatomyositis (DM) complicated with macrophage activation syndrome (MAS). The demographic and clinical characteristics of five patients diagnosed with DM complicated with MAS hospitalized in the Department of Rheumatology and Immunology, Peking University People ' s Hospital from 2011 to 2021 were collected. The results of clinical manifestations, laboratory tests, immunological features, treatments and prognosis were analyzed and summarized. In this study, five female patients in Peking University People's Hospital with an average age of 63.8 (44.0-83.0) years and an average disease duration of 16.1 (1.5-48.0) months. All the patients had typical DM rash (such as heliotrope sign, V/shawl sign or Gottron's sign/papules). They all had muscle involvement (including myalgia or muscle weakness). Two patients had positive myositis-specific antibodies (MSAs), in which case 1 had anti-TIF1-γ antibody and case 5 had anti-NXP-2 antibody. Four patients had interstitial lung disease except case 3. All of the cases developed MAS in the active stage of DM. Common manifestations of MAS in these five patients included high-grade fever, cytopenia, decreased fibrinogen, elevated ferritin and increased soluble CD25. Case 1 presented with neutropenia (0.6×109 /L), thrombocytopenia (26.0×109 /L), hypofibrinogenemia (0.9 g/L), markedly elevated ferritin (26 331.0 μg/L), decreased NK cell activity. Case 2 had anaemia (hemoglobin 81.0 g/L), thrombocytopenia (55.0×109 /L), hypertriglyceridemia (4.7 mmol/L), hypofibrinogenemia (1.2 g/L), elevated ferritin (>100 000.0 μg/L), hemophagocytosis in bone marrow. Case 3 had anaemia (hemoglobin 88 g/L), decreased fibrinogen (1.9 g/L), increased ferritin (>27 759.0 μg/L), splenomegaly, hemophagocytosis in bone marrow. Case 4 suffered from neutropenia(0.3×109 /L), anaemia(hemoglobin 78 g/L), hypertriglyceridemia (4.2 mmol/L), hypofibrinogenemia (0.9 g/L), increased ferritin (>100 000.0 μg/L), and decreased NK cell activity. Case 5 presented anaemia (hemoglobin 60.0 g/L), thrombocytopenia (67.0×109 /L), hypertriglyceridemia (12.7 mmol/L), decreased fibrinogen (1.1 g/L), and elevated ferritin (>923.0 μg/L). All the patients were treated with methylprednisone pulse therapy (200-500 mg) combined with cyclosporine while case 5 received rituximab after methylprednisone pulses. In addition, case 3 also received the combination of mycophenolate mofetil. Case 1 was given etoposide while case 4 was treated with cyclophosphamide and repeated plasmapheresis at the same time. Moreover, intravenous immunoglobulin was added meantime apart from case 3. The condition of four patients improved significantly, nevertheless case 4 experienced recurred pulmonary symptoms and died of respiratory failure. As for complications about infection, case 2 had bacterial infection with high level procalcitonin (PCT) before MAS treatment and condition was improved after empiric antibacterial therapy. Case 3 had cytomegalovirus DNAemia before diagnosis of MAS and viral titer turned negative after ganciclovir therapy. After treatment of MAS, four patients developed cytomegalovirus DNAemia except case 3, in which case 5 was co-infected with bacteria. To sum, DM complicated with MAS is relatively rare, and its patients are of ten in life-threatening condition. Early detection, treatment and prevention of infection during treatment are critical to improve the prognosis.

Key words: Dermatomyositis, Macrophage activation syndrome, Myositis specific autoantibodies, Infection, Prognosis

中图分类号: 

  • R593.26

图1

病例3骨髓涂片可见噬血现象"

1 Bohan A , Peter JB . Polymyositis and dermatomyositis (first of two parts)[J]. N Engl J Med, 1975, 292 (7): 344- 347.
doi: 10.1056/NEJM197502132920706
2 Lundberg IE , Tjarnlund A , Bottai M , et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups[J]. Ann Rheum Dis, 2017, 76 (12): 1955- 1964.
doi: 10.1136/annrheumdis-2017-211468
3 Henter JI , Horne A , Arico M , et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis[J]. Pediatr Blood Cancer, 2007, 48 (2): 124- 131.
doi: 10.1002/pbc.21039
4 Lerkvaleekul B , Vilaiyuk S . Macrophage activation syndrome: Early diagnosis is key[J]. Open Access Rheumatol, 2018, 10, 117- 128.
doi: 10.2147/OARRR.S151013
5 Kumakura S , Murakawa Y . Clinical characteristics and treatment outcomes of autoimmune-associated hemophagocytic syndrome in adults[J]. Arthritis Rheumatol, 2014, 66 (8): 2297- 2307.
doi: 10.1002/art.38672
6 Liang J , Xu D , Sun C , et al. Hemophagocytic lymphohistiocytosis: Prevalence, risk factors, outcome, and outcome-related factors in adult idiopathic inflammatory myopathies[J]. J Rheumatol, 2020, 47 (10): 1532- 1540.
doi: 10.3899/jrheum.190542
7 Minoia F , Davi S , Horne A , et al. Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: A multinational, multicenter study of 362 patients[J]. Arthritis Rheumatol, 2014, 66 (11): 3160- 3169.
doi: 10.1002/art.38802
8 Tang S , Li S , Zheng S , et al. Understanding of cytokines and targeted therapy in macrophage activation syndrome[J]. Semin Arthritis Rheum, 2021, 51 (1): 198- 210.
doi: 10.1016/j.semarthrit.2020.12.007
9 Kostik MM , Dubko MF , Masalova VV , et al. Identification of the best cutoff points and clinical signs specific for early recognition of macrophage activation syndrome in active systemic juvenile idiopathic arthritis[J]. Semin Arthritis Rheum, 2015, 44 (4): 417- 422.
doi: 10.1016/j.semarthrit.2014.09.004
10 Fardet L , Galicier L , Lambotte O , et al. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome[J]. Arthritis Rheumatol, 2014, 66 (9): 2613- 2620.
doi: 10.1002/art.38690
11 Schulert GS . The storm beneath the storm: MAS-HLH in inflammatory myopathies[J]. J Rheumatol, 2020, 47 (10): 1461- 1463.
doi: 10.3899/jrheum.191274
12 Gono T , Kawaguchi Y , Ozeki E , et al. Serum ferritin correlates with activity of anti-MDA5 antibody-associated acute interstitial lung disease as a complication of dermatomyositis[J]. Mod Rheumatol, 2011, 21 (2): 223- 227.
doi: 10.3109/s10165-010-0371-x
13 La Rosee P , Horne A , Hines M , et al. Recommendations for the management of hemophagocytic lymphohistiocytosis in adults[J]. Blood, 2019, 133 (23): 2465- 2477.
doi: 10.1182/blood.2018894618
14 Canna SW , Girard C , Malle L , et al. Life-threatening NLRC4-associated hyperinflammation successfully treated with IL-18 inhibition[J]. J Allergy Clin Immunol, 2017, 139 (5): 1698- 1701.
doi: 10.1016/j.jaci.2016.10.022
15 Gabr JB , Liu E , Mian S , et al. Successful treatment of secondary macrophage activation syndrome with emapalumab in a patient with newly diagnosed adult-onset Still's disease: Case report and review of the literature[J]. Ann Transl Med, 2020, 8 (14): 887.
doi: 10.21037/atm-20-3127
16 Ahmed A , Merrill SA , Alsawah F , et al. Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: An open-label, single-centre, pilot trial[J]. Lancet Haematol, 2019, 6 (12): e630- e637.
doi: 10.1016/S2352-3026(19)30156-5
17 Verweyen E , Holzinger D , Weinhage T , et al. Synergistic signaling of TLR and IFNalpha/beta facilitates escape of IL-18 expression from endotoxin tolerance[J]. Am J Respir Crit Care Med, 2020, 201 (5): 526- 539.
doi: 10.1164/rccm.201903-0659OC
18 Wu J, Sun L, Tang X, et al. Effective therapy of tocilizumab on systemic juvenile idiopathic arthritis associated refractory macrophage activation syndrome[J]. Mod Rheumatol, 2021[2022-08-01]. https://doi.org/10.1093/mr/roab119.
19 Fujita Y , Fukui S , Suzuki T , et al. Anti-MDA5 antibody-positive dermatomyositis complicated by autoimmune-associated hemophagocytic syndrome that was successfully treated with immunosuppressive therapy and plasmapheresis[J]. Intern Med, 2018, 57 (23): 3473- 3478.
doi: 10.2169/internalmedicine.1121-18
20 Kaieda S , Yoshida N , Yamashita F , et al. Successful treatment of macrophage activation syndrome in a patient with dermatomyositis by combination with immunosuppressive therapy and plasmapheresis[J]. Mod Rheumatol, 2015, 25 (6): 962- 966.
doi: 10.3109/14397595.2013.844402
21 Komiya Y , Saito T , Mizoguchi F , et al. Hemophagocytic syndrome complicated with dermatomyositis controlled successfully with infliximab and conventional therapies[J]. Intern Med, 2017, 56 (23): 3237- 3241.
doi: 10.2169/internalmedicine.7966-16
22 Sasaki H , Kohsaka H . Current diagnosis and treatment of polymyositis and dermatomyositis[J]. Mod Rheumatol, 2018, 28 (6): 913- 921.
doi: 10.1080/14397595.2018.1467257
23 Gavand PE , Serio I , Arnaud L , et al. Clinical spectrum and therapeutic management of systemic lupus erythematosus-associated macrophage activation syndrome: A study of 103 episodes in 89 adult patients[J]. Autoimmun Rev, 2017, 16 (7): 743- 749.
doi: 10.1016/j.autrev.2017.05.010
[1] 张铃福, 陈明, 赵小宇, 王港, 崔龙, 凌晓锋, 王立新, 徐智, 郭丽梅, 侯纯升. 原发灶局限于胆囊壁内胆囊癌大体分型及其与预后和癌前病变的相关性[J]. 北京大学学报(医学版), 2026, 58(1): 184-189.
[2] 耿芸玲, 刘超, 杨萍, 郑佳佳, 沈宁, 杜毅鹏. 医院获得性肺炎患者肺炎克雷伯菌多部位感染的临床特征及毒力基因分布[J]. 北京大学学报(医学版), 2026, 58(1): 201-207.
[3] 彭嘉婧, 崔莉. 以眼部病变首发的结节病的临床特征及预后[J]. 北京大学学报(医学版), 2025, 57(6): 1061-1066.
[4] 高雅静, 李正芳, 马梦思, 武丽君. SII和SIRI对白塞病葡萄膜炎的风险预测及疾病活动度和预后的评估[J]. 北京大学学报(医学版), 2025, 57(6): 1067-1073.
[5] 郭博达, 陆敏, 王国良, 张洪宪, 刘磊, 侯小飞, 赵磊, 田晓军, 张树栋. 肾透明细胞癌与非透明细胞癌伴静脉癌栓患者的临床病理特征及预后比较[J]. 北京大学学报(医学版), 2025, 57(4): 644-649.
[6] 李伟浩, 李晶, 张学民, 李伟, 李清乐, 张小明. 术中回收式自体输血对颈动脉体瘤切除术后肿瘤预后的影响[J]. 北京大学学报(医学版), 2025, 57(2): 272-276.
[7] 王紫薇, 李闵, 高慧, 邓芳. 链球菌感染与过敏性紫癜肾炎患儿肾损害的相关性[J]. 北京大学学报(医学版), 2025, 57(2): 284-290.
[8] 刘爱春, 赵慧萍, 武蓓, 郑姝颖, 左力, 王梅. 腹膜透析相关性腹膜炎拔管患者导管内细菌生物膜的形成[J]. 北京大学学报(医学版), 2025, 57(1): 161-165.
[9] 潘苇, 李云, 罗俊佳, 李春, 叶华, 李雪, 贾园. 系统性硬化症患者新型冠状病毒感染特点及疫苗接种效果:一项单中心队列研究[J]. 北京大学学报(医学版), 2024, 56(6): 1041-1046.
[10] 毛雅晴, 陈震, 于尧, 章文博, 刘洋, 彭歆. 2型糖尿病对口腔鳞状细胞癌患者预后的影响[J]. 北京大学学报(医学版), 2024, 56(6): 1089-1096.
[11] 欧俊永,倪坤明,马潞林,王国良,颜野,杨斌,李庚午,宋昊东,陆敏,叶剑飞,张树栋. 肌层浸润性膀胱癌合并中高危前列腺癌患者的预后因素[J]. 北京大学学报(医学版), 2024, 56(4): 582-588.
[12] 刘帅,刘磊,刘茁,张帆,马潞林,田晓军,侯小飞,王国良,赵磊,张树栋. 伴静脉癌栓的肾上腺皮质癌的临床治疗及预后[J]. 北京大学学报(医学版), 2024, 56(4): 624-630.
[13] 虞乐,邓绍晖,张帆,颜野,叶剑飞,张树栋. 具有低度恶性潜能的多房囊性肾肿瘤的临床病理特征及预后[J]. 北京大学学报(医学版), 2024, 56(4): 661-666.
[14] 周泽臻,邓绍晖,颜野,张帆,郝一昌,葛力源,张洪宪,王国良,张树栋. 非转移性T3a肾细胞癌患者3年肿瘤特异性生存期预测[J]. 北京大学学报(医学版), 2024, 56(4): 673-679.
[15] 方杨毅,李强,黄志高,陆敏,洪锴,张树栋. 睾丸鞘膜高分化乳头状间皮肿瘤1例[J]. 北京大学学报(医学版), 2024, 56(4): 741-744.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!